Advertisement

Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry

  • Chong XuEmail author
  • Yibo YinEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2108)

Abstract

Chimeric antigen receptor T cells (CAR T cells) therapy is one kind of immunotherapy that has revolutionally changed the landscape of immunotherapy and been approved by the FDA from 2017 for several blood malignancies. To bring new CAR T cells to clinic, every new CAR need to test in vitro for antigen recognition, tumor cell killing capacity, and off-target cytotoxicity effect. Detecting the secretion of cytokines upon engagement of CAR T cells with tumor antigens is routinely applied to assess these CAR functions. Here we describe coupling of intracellular cytokine staining and multicolor flow cytometry to measure CAR T cells activation upon antigen stimulation.

Key words

Chimeric antigen receptor T cells CAR T cells Intracellular cytokine staining Flow cytometry T cell activation Immunotherapy 

References

  1. 1.
    Khalil DN, Smith EL, Brentjens RJ et al (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:273–290CrossRefGoogle Scholar
  2. 2.
    Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62–68CrossRefGoogle Scholar
  3. 3.
    Yang XH (2017) A new model T on the horizon? Cell 171:1–3CrossRefGoogle Scholar
  4. 4.
    Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733CrossRefGoogle Scholar
  5. 5.
    Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507–1517CrossRefGoogle Scholar
  6. 6.
    Maus MV, June CH (2016) Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 22:1875–1884CrossRefGoogle Scholar
  7. 7.
    Maude SL, Barrett DM, Rheingold SR et al (2016) Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia. Blood 128:217CrossRefGoogle Scholar
  8. 8.
    Johnson LA, Scholler J, Ohkuri T et al (2015) Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 7:275ra22CrossRefGoogle Scholar
  9. 9.
    Yin Y, Boesteanu AC, Binder ZA et al (2018) Checkpoint blockade reverses Anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics 11:20–38CrossRefGoogle Scholar
  10. 10.
    Benmebarek MR, Karches CH, Cadilha BL et al (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20:E1283CrossRefGoogle Scholar
  11. 11.
    Janeway CA Jr, Travers P, Walport M et al (eds) (2001) Immunobiology: the immune system in health and disease, 5th edn. Garland Publishing, New York, NYGoogle Scholar
  12. 12.
    Begent RH, Verhaar MJ, Chester KA et al (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2:979–984CrossRefGoogle Scholar
  13. 13.
    Leehan KM, Koelsch KA (2015) T cell ELISPOT: for the identification of specific cytokine-secreting T cells. Methods Mol Biol 1312:427–434CrossRefGoogle Scholar
  14. 14.
    Betts MR, Koup RA (2004) Detection of T-cell degranulation: CD107a and b. Methods Cell Biol 75:497–512CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Center for Cellular Immunotherapies, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.The Parker Institute for Cancer Immunotherapy, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of Pathology and Laboratory Medicine, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  4. 4.Department of Medicine, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  5. 5.Department of Neurosurgery, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  6. 6.The Fourth Section of Department of NeurosurgeryThe First Affiliated Hospital of Harbin Medical UniversityHarbinP.R. China

Personalised recommendations